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ABSTRACT
T
he beginning of this millennium has seen dramatic
advances in genomic research. Milestones such as the
complete sequencing of the human genome and of
many other species were achieved and complemented by the
systematic discovery of variation at the single nucleotide
(SNP) and whole segment (copy number polymorphism) level.
Currently most genomics research efforts are concentrated
on the production of whole genome functional annotations,
as well as on mapping the epigenome by identifying the
methylation status of CpGs, mainly in CpG islands, in
different tissues. These recent advances have a major impact
on the way genetic research is conducted and have
accelerated the discovery of genetic factors contributing to
disease. Technology was the critical driving force behind
genomics projects: both the combination of Sanger
sequencing with high-throughput capillary electrophoresis
and the rapid advances in microarray technologies were keys
to success. MALDI-TOF MS–based genome analysis
represents a relative newcomer in this ﬁeld. Can it establish
itself as a long-term contributor to genetics research, or is it
only suitable for niche areas and for laboratories with a
passion for mass spectrometry? In this review, we will
highlight the potential of MALDI-TOF MS–based tools for
resequencing and for epigenetics research applications, as
well as for classical complex genetic studies, allele
quantiﬁcation, and quantitative gene expression analysis. We
will also identify the current limitations of this approach and
attempt to place it in the context of other genome analysis
technologies.
Introduction
It is now commonly accepted that genetics plays a key role
in the occurrence of common diseases, from diabetes and
cancer to psychiatric disorders. At the same time, genetic
approaches have been mostly successful in identifying the
genetic component of Mendelian diseases. The construction
of physical and genetic maps for the human genome [1–3] was
followed by the complete human genome sequence and
analysis [4]. This has allowed the experimental [5] and
computational identiﬁcation of transcribed sequences, and
driven the execution of cost-effective positional cloning
approaches, leading to the identiﬁcation of about 1,000 genes
causing Mendelian diseases. The completion of the human
sequence was rapidly followed by the identiﬁcation of the
most common variations in the human genome, namely single
nucleotide polymorphisms (SNPs), estimated at 10 million [6].
These major advances are being complemented by efforts
aimed at the detection of the methylation status of CpG
islands (Epigenome Project) [7] and by large-scale gene
expression studies aiming to link gene expression patterns to
genome variation [8].
The underlying force for these major advances is a
collection of enabling technologies, spearheaded by Sanger
sequencing combined with capillary electrophoresis and
microarray-based technologies. Current efforts are
concentrated towards dramatically improving the cost
efﬁciency of whole genome sequencing approaches to achieve
the goal of sequencing one genome a day at $100,000 each,
and potentially for $10,000 or less [9].
One of the technologies that has been put forward as an
alternative to the Sanger sequencing/capillary electrophoresis
combination is matrix-assisted laser desorption/ionisation,
time-of-ﬂight mass spectrometry (MALDI-TOF MS). MALDI-
TOF MS was introduced, and has established itself, as the tool
of choice in proteomics applications, while the full potential
for DNA analysis was demonstrated in 1995 [10] and for RNA
in 1998 [11].
In brief, for MALDI-TOF MS analysis single-stranded
nucleic acid molecules of 3–29 bp in length (1,000–8,600
Dalton range) need to be generated and deposited on a
matrix (e.g., 3-hydroxy picolinic acid). The analyte/matrix
molecules are then irradiated by a laser inducing their
desorption and ionisation, upon which the molecules pass
through a ﬂight tube connected to a detector on the other
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which is proportional to the mass of the individual molecules.
The main advantage of the method is that it directly measures
an intrinsic physical property of the molecules, namely their
mass, and at a very high speed (about 100 ls). Limitations lie
in the size of the DNA molecules that can be detected intact
to less than 100 bp (due to size-dependent fragmentation
during the MALDI process); and that the analytes must be
free from ion adducts which lead to mass distortion. Efforts
in the last ten years concentrated on developing simple,
robust, homogeneous, and automatable assays suitable for a
wide spectrum of genomic applications.
SNP Genotyping
One of the most effective uses of MALDI-TOF MS in
genome analysis is for SNP genotyping. Several methods have
been developed for this application based on either a locus-
speciﬁc PCR step followed by a primer extension, invader
reaction, or hybridization steps with or without exonuclease
digestion. The products are then detected by MALDI-TOF
MS (reviewed in [12]). From all these possibilities, the most
widely used are the GOOD assay [13], the PinPoint [14], the
GenoSNIP (Bruker Daltonics, Billerica, Massachusetts, United
States) and the MassEXTEND (Sequenom, San Diego,
California, United States) [15]. The homogeneous
MassEXTEND reaction (hME) represented an important step
forward since it was the only truly homogeneous assay that is
performed in one tube (well) using unmodiﬁed primers, and
therefore best suited to high throughput analyses. The assay is
based on generating PCR products, which are subsequently
treated with shrimp alkaline phosphatase, followed by primer
extension reactions using Thermosequenase (GE Healthcare,
Bucks, United Kingdom) and stop mixes containing cocktails
of ddNTPs and dNTPs. Adduct-forming ions are removed by
adding an anion exchange resin. MALDI-TOF analysis is
performed by piezo electrically dispensing 15 nl of the
reaction products into silica-based chip arrays containing
matrix spots (3-hydroxy picolinic acid) in a 384 format. A
batch of ten of these chips can be loaded into a typical
MALDI instrument (e.g., Bruker Biﬂex II/III or Autoﬂex I/II),
allowing the analysis of 3,840 reactions in a few hours.
To be cost effective, the SNP assays must be multiplexed at
a high level. Although 12-plex reactions have been
demonstrated [16], designing multiplex PCR assays involves
dealing with the competing parameters of speciﬁcity and
uniform cycling conditions, and minimising interactions
between primer sets.
A step towards optimising multiplexed PCR design was
achieved recently through the generation of a set of assay
design algorithms that screen out primer interactions and
perform simultaneous BLAT searches on the human genome
for speciﬁcity optimisations, thus allowing automated design
of primers for 20–30 plex reactions [17]. Sequenom optimised
the primer extension reactions for MALDI-TOF MS by using
acyclic mass modiﬁed base terminators that achieve at least
16 Dalton gaps between the four possible bases incorporated
into a single base extension. Finally, noncomplementary bases
are added to the 59 of the extension primers to uniformly ﬁll
the 4,500–9,000 Dalton range of the spectrum. In parallel, the
PCR and primer extension reaction conditions were
optimised. As a result, this type of assay, called iPLEX,
features a high design efﬁciency, low assay dropout rates, and
high pass rates (about 95% in our hands) at typically the 26–
29 plex level (Figure 2). At the same time, iPLEX is cost
efﬁcient, able to offer a very competitive cost in the ‘‘few
cent’’ per genotype category, while the ability to process high
sample numbers is retained. Due to the high efﬁciency PCR
conditions, extra care is needed to avoid contaminations.
hME is suitable for large-scale collaborative projects
requiring a mid-range number of SNPs (10–400) and high
numbers of samples [18] and has also contributed to the ﬁrst
phase of the HapMap project. It is also suitable for projects
requiring validation steps of ultra-high-throughput SNP-
based disease association studies, as well as for genetic studies
involving model organisms. A recent example is the
development of SNP assays within the framework of the
domestic dog genome sequencing project [19]. The ability to
design and obtain primers within a very short time enabled us
to perform rapid candidate gene analysis by hME using as few
as two SNPs and 800 samples up to ten SNPs and 2,215
samples for association studies [20,21]. In addition, 200 SNPs
have been analysed in 360 individuals to validate LD data [22].
The hME assay is the cost-effective choice where 2–9 plexes
are sufﬁcient on 384 samples or more, while iPLEX is very
cost-effective when the assays involve multiples of 25–29 SNPs
on 384 samples or more. In both cases, 7,680 samples can be
processed within a few days.
Comparable alternative SNP genotyping technologies in
terms of throughput include SNPStream from Beckman
Coulter (Fullerton, California, United States) [23] and SNPlex
from ABI (Foster City, California, United States) [24], both of
which have the capability to multiplex 12–48 SNP assays in a
384-well format. SNPStream is based on primer extension
and product capture on an array, while SNPlex is based on
oligonucleotide ligation and PCR, followed by hybridization
DOI: 10.1371/journal.pgen.0020100.g001
Figure 1. MALDI-TOF Mass Spectrometry
The analyte is deposited on a matrix crystal containing spot. A laser is
fired at the matrix leading to the desorption of the analytes and their
ionisation. For the majority of DNA analyses, the matrix is designed to
produce positive ions. The molecules accelerate into the flight tube
where they fly towards the detector on the right. Low mass molecules
arrive in a shorter time than heavier ones and molecules of different
mass are thus separated (1). After data processing, a spectrum is
produced with relative intensity on the y-axis and mass in Daltons on the
x-axis (2).
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separation by capillary electrophoresis. Equipment costs
depend on the level of automation required, but are similar
between Sequenom and ABI, while the Beckman Coulter
equipment is less expensive. In terms of consumable cost/
genotype, the iPLEX reaction is the most cost-efﬁcient due to
the combination of low SNP assay speciﬁc and general
reagents costs. In terms of pass rate and accuracy, both
MassEXTEND and SNPstream were used within the
framework of the GenomEUtwin project [18], and
comparable results were obtained. The MALDI-TOF–based
methods have the advantage over other assays in that the user
is in total control of the assay design process and is able to
modify procedures and to develop his/her own protocols. The
hME/iPLEX type assays have the additional advantage of
requiring only unmodiﬁed primers, which allows for a
minimal gap between SNP selection, design, and project start.
Determining SNP haplotypes is important for many
research and clinical applications ranging from association
studies to pharmacogenetics. Haplotypes are constructed
either using pedigrees and statistical methods, or allele-
speciﬁc PCR, or somatic cell hybrids [25]. Ivo Gut and
colleagues combined allele-speciﬁc PCR with MALDI-TOF
MS–based genotyping to determine haplotypes within a 2–4
kb range at high throughput [26]. Ding and Cantor took
advantage of the sensitivity offered by the MALDI-TOF MS
analysis and combined it with high efﬁciency PCR on highly
diluted (3 pg) DNA samples to achieve molecular haplotyping
[27]. The method, called M1-PCR, allows the direct
determination of haplotypes within up to 24 kb of DNA.
Although this latter method is able to generate haplotypes of
longer distances than allele-speciﬁc PCR-based techniques, it
is very sensitive to contamination.
Furthermore, MALDI-TOF MS–based genotyping has also
found its way into many clinical genetic applications for SNP
or known mutation detection such as in cystic ﬁbrosis [28–
31], and in other clinical applications involving the typing of
bacteria and viruses [32,33].
Quantitative DNA Analysis Applications
In MALDI-TOF MS analyses, the amount of analyte that is
co-crystallized with the matrix and then ionized by laser
excitation is proportional to the areas under the detected
peaks. This allows the relative quantiﬁcation of the molecules
present in the analyte by calculating the peak area ratios. In
this setting, variation in peak ratios in a large number of
samples can be easily determined, and this quantitative data
is one of the strengths of this method. The relative
quantitative power of the approach has been used
successfully to determine SNP allele frequencies in DNA
pools [34–36] in allelotyping experiments. The area under the
peaks corresponding to the two alleles is measured and used
to determine a ratio, which is normalised to correct the skew
due to different extension efﬁciencies using the ratio
obtained from nonpooled genomic DNA (where we expect a
1:1 ratio between the two alleles). For accuracy, each
measurement involves at least three technical replicates.
MALDI-TOF MS emerged as one of the most accurate
allelotyping techniques when compared with Pyrosequencing
(Biotage, Uppsala, Sweden), TaqMan, and SNaPshot (Applied
Biosystems) [37]. This method has been applied to disease
association studies, particularly at a time when genotyping
costs were relatively high [38,39]. Even if DNA pooling
achieves considerable cost savings and has now been applied
on high density Affymetrix GeneChip mapping arrays [40],
generating good quality DNA pools requires careful
adjustment of each individual DNA, particularly for large
numbers of samples (thousands), and therefore becomes
labour-intensive. This limitation may be overcome by
introducing a whole genome ampliﬁcation step, whereby the
DOI: 10.1371/journal.pgen.0020100.g002
Figure 2. Example of a 29plex iPLEX Reaction
For the iPLEX reactions, the primers are split into three groups according to the position of their respective mass peaks to use the whole spectrum. The
concentrations of the three groups are adjusted so that peaks detected at the low mass end of the spectrum have a similar peak height to peaks at the
high end of the spectrum. Three examples are highlighted in different colours in different areas of the spectrum. The unextended primer peak is marked
by an asterisk and dotted arrow, while the other solid arrows indicate the two different alleles. In red, a homozygous genotype example is shown. In
green and blue, two heterozygous alleles are shown. Note the similar peak heights at which extension products corresponding to the two alleles of an
SNP are detected and their relative proximity. This proximity enables a higher accuracy to be achieved in the assay by applying the same level of local
background subtraction and by eliminating misinterpretations resulting from small peaks, detected just above background, at the expected mass.
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quite homogeneous [41]. The MALDI-TOF MS–based
methods utilising DNA pools would be useful for allelotyping
studies involving either candidate functional SNPs as shown
in Butcher et al. [42] or to validate results from high-density
SNP arrays [43].
Detection of Indels Associated with MSI and Short
Tandem Repeats
In addition to SNPs, another important polymorphism is
represented by insertions and deletions (indels), some of
which can be disease-causing mutations or associated with
microsatellite repeat instability (MSI) in the form of length
variation of short repetitive sequences. Repeat instability as a
form of mutation is linked to a number of disease conditions
[44] and cancer [45]. To date, indels and MSIs are detected
using electrophoresis and DNA sequencing, which apart from
being time-consuming and expensive, are not particularly
sensitive in detecting quantitative differences. To solve this
problem, MALDI-TOF MS has been applied in combination
with assays utilising primer extension [46] or the generation
of RNA fragments [47]. Bonk et al. [46] investigated MSIs
linked to neoplastic lesions (colorectal tumours, cell lines,
and normal control samples) and used primers designed to
anneal directly at the 59 of short mononucleotide repeats.
Analysis of the primer extension products resulted in speciﬁc
peak patterns, allowing the identiﬁcation of unstable repeats
in the tumour samples. Another approach was used by
Sasayama et al. [47]. Brieﬂy, in vitro transcription of PCR
products was followed by cleavage at 59 and 39 of the indel site
using molecular scissors and analysis of the resulting RNA
fragment by MALDI-TOF, as demonstrated in the analysis of
the ApoE3 gene.
A related approach involving ribozymes was used by Krebs
et al. [48] to type short tandem repeat sequences. The method
was subsequently reﬁned to utilize base speciﬁc cleavage of
RNA molecules using RNase T1 [49] (see sequencing below).
Gene Expression Analysis
Now that the HapMap project has produced working assays
for about one million SNPs [50], future efforts will
concentrate more on the identiﬁcation and characterization
of functional variants linked to phenotypes [51]. There is
great interest in the identiﬁcation of genetic elements
inﬂuencing gene expression levels [52]: measuring relative
expression levels of speciﬁc alleles carrying coding
polymorphisms (with potential functional effects) and
identifying the effect of DNA polymorphisms on the way
hnRNA is spliced to produce mRNA. Once functional
variants have been identiﬁed, it will be possible to link them
to particular phenotypes, covering a broad spectrum from
common disease to infection resistance and drug responses.
The allelotyping approach described in the quantitative
analysis applications can be adapted for allele-speciﬁc
expression analysis involving coding SNPs or SNPs in UTRs.
Brieﬂy, the RNA is converted to cDNA by reverse
transcription, followed by PCR of the segment containing the
SNP and the interrogation of the SNP using a primer
extension–based approach. In heterozygous individuals, we
would expect two peaks in MALDI-TOF MS analysis. The area
under the peaks corresponding to the two alleles is measured
and used to determine a ratio similar to allelotyping [53]. The
method has been used successfully to determine allele-
speciﬁc expression at the IL-8 locus [54]. In the absence of a
transcribed SNP, it is possible to use the HaploChip
technique [55] to assay for SNP alleles present near the
transcription start site (within 1 kb) using Polymerase II
loading as a marker for transcriptional activity. Antibodies
against phosphorylated Pol II are used to immunoprecipitate
cross-linked Pol II-DNA complexes. Upon reversal of the
cross-link, the segment containing the transcription start site
is ampliﬁed by PCR and the SNPs within the PCR product are
interrogated by primer extension and MALDI-TOF MS. A
distortion in the relative ratio of the two alleles indicates an
imbalance in their respective levels of transcription.
Total levels of expression can be determined by the real
competitive PCR technique (RC-PCR) [56]. This also involves
converting RNA to cDNA and ampliﬁcation of a segment by
PCR (usually short amplicons 70–90 bp long). In addition, a
competitor oligo of known concentration with the same
sequence as the PCR region, apart from one single base close
to the middle of the amplicon, is ampliﬁed in the same
reaction. This type of sequence eliminates differences in the
ampliﬁcation rates between target and competitor and can be
used to titrate the amount of target present in the total cDNA
(see Figure 3). Typically 7–15 different concentrations of
competitor are used and the results plotted in a titration
curve. We have applied linear regression analysis using the
software package TITAN, and this can be used to analyze data
from any type of competitor PCR-based approach [57]. We
have compared RC-PCR to real time PCR and found that the
main advantage of RC-PCR was the relatively little
optimisation required for each assay as compared with SYBR
green–based real time PCR. Since the assay uses an internal
standard, both competitor and cDNA are ampliﬁed under the
same conditions and therefore the results are relatively
insensitive to nonspeciﬁc PCR products or primer-dimers. In
addition, the two rounds of ampliﬁcation (PCR followed by
primer extension) allow for two levels of speciﬁcity, ensuring
that only speciﬁc products are detected by MALDI-TOF MS
analysis. Disadvantages include the need to prepare dilution
series; the addition of reaction components to each well can
be complicated and laborious, ideally requiring the use of
liquid handling systems and further post-PCR processing. The
RC-PCR method is suited to the simultaneous analysis of 70–
700 genes rather than one (or small number of) gene(s) in one
(or few) sample(s) [57], particularly when combined with
iPLEX. The method is also suitable for detecting copy
number changes in the genome and is particularly suitable
for the validation of expression-proﬁling results, or multiple
signature genes [57]. Finally, primer extension–based
techniques can be used effectively in multiplexed assays to
identify RNA splice variants by interrogating diagnostic bases
at the splice junctions [58].
DNA and RNA Sequencing
The advantages of MALDI-TOF MS over gel-based
separation methods can be summarised as high resolution,
high speed, and an absence of compression zones.
Considerable amount of work has gone into establishing this
technology as a viable alternative to capillary electrophoresis
of Sanger sequencing or enzymatic digestion reactions.
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capturable dideoxynucleotides, and the generation of RNA
ladders from a DNA template have been reviewed extensively
elsewhere [59,60]. Despite these developments, the read
lengths obtained at a maximum of approximately 100 bp are
not competitive when compared with Sanger sequencing/
capillary electrophoresis [60,61]. As a result, alternative
strategies are being pursued to increase throughput and cut
costs. However, MALDI-TOF MS is well-suited to analysing
RNA [62,63], which is more stable than DNA under MALDI
conditions. In RNA analysis applications, this can be applied
to identify post-transcriptional modiﬁcations in ribosomal
RNA. This has been investigated in the context of resistance
towards antibiotics mediated through post-transcriptional
modiﬁcation of rRNA using RNase digestion–based protocols
[64]. Similar RNase digestion–based protocols have also been
used to investigate RNA secondary structure to optimise the
sequence of antisense oligonucleotides [65]. The assay
involves using oligodeoxynucleotides that are used to form
RNA–oligodeoxynucleotides duplexes which are subsequently
recognised and digested by RNaseH. MALDI-TOF MS is the
method of choice to analyse the resulting fragments.
For DNA analysis, methods have been developed that
involve in vitro transcription of DNA into RNA. RNA
fragments are generated by base speciﬁc cleavage and
analysed by MALDI-TOF MS, with the aim of identifying
basepair changes in the sequence as compared with a
computationally predicted outcome [66–69] (Figure 4A).
These methods (for example MassCLEAVE (hMC) by
Sequenom) are suited to resequencing projects for SNP and
frameshift mutations detection (see Figure 4B) as well as SNP
discovery using PCR products with a length of 200-1500 bp.
More complex mutations involving longer indels or
combinations thereof are difﬁcult to determine correctly
without further improvements in the algorithms (K. Kaur and
J. Ragoussis, unpublished data). Although further
bioinformatic optimisations have been incorporated which
allow reactions to be multiplexed, the wide use of capillary
electrophoresis to analyse Sanger-sequencing reaction
products combined with the wealth of algorithms developed
to interpret electropherograms and to detect mutations
mean that it is likely that MALDI-TOF MS–based sequencing
will remain a niche method. Considerable investment will also
be required to compete against microarray-based
resequencing, proven to be effective in detecting point
mutations [70]. However, there is one exciting application
that is a result of the efforts to develop MALDI-TOF MS–
based sequencing approaches and that is methylation
detection.
DNA Methylation Analysis
DNA methylation at CpG sites in the genome contributes
to several inherited human genetic diseases [71], and it has
been postulated to contribute in a signiﬁcant way to complex
disease susceptibility [72]. The involvement of DNA
methylation in gene expression regulation, genome stability,
and imprinting has prompted the development and
implementation of the Human Epigenome Project. This
project will generate a genome-wide DNA methylation proﬁle
of the human genome with the analysis of different
individuals and multiple tissues [7]. The project is under way
and the proﬁle of the human major histocompatibility
complex, the target of the Human Epigenome Project pilot
phase, has been recently completed [73]. The identiﬁcation of
the epigenetic factors contributing to disease etiology needs
DOI: 10.1371/journal.pgen.0020100.g003
Figure 3. RC-PCR Experiment
(A) A triplex assay for the genes BNIP3, CA9, and NDRG1 is shown. Using a high competitor concentration (10
 12M), competitor is predominantly PCR-
amplified and only the primer extension products resulting from the competitor oligos (blue arrows, top graph) are detected. Using low competitor
concentrations (10
 16M), cDNA is predominantly PCR-amplified and only the primer extension products resulting from the cDNA are detected (blue
arrows, bottom graph). The equivalence point, whereby an equal area of competitor and cDNA peaks is derived, would lie at a competitor
concentration of between 10
 12 M and 10
 16 M.
(B) Output of the TITAN software (http://www.well.ox.ac.uk/;tprice/titan) showing linear regression analysis of two samples (red and black) for BNIP3
expression. x-axis: competitor concentrations; y-axis (left) is the log 10 ratio of test (cDNA) to competitor signal. The equivalence point is given by the
concentration at which y¼0, and is calculated by interpolation (black/red arrows). An approximated difference in expression is detected between the
two samples.
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Many technologies have been developed [74], but only some
of them lend themselves to high-throughput application.
Among these, several are based on the detection of C/T SNPs
that are chemically induced at CpG sites in the genome
sequence by bisulﬁte treatment (where a C will be detected if
methylation is present) [75]. Direct sequencing has been used,
and several technologies developed for SNP detection have
been adapted to bisulﬁte treatment–based methylation
detection: including single nucleotide primer extension
(SNuPE) combined with dot-blot [76] or with ion pair reverse
phase high performance liquid chromatography (IP RP
HPLC) [77], capillary electrophoresis [78,79], pyrosequencing
technology [78,80,81], probe-based [82], and melting curve–
based real-time PCR methods [83].
Whole genome approaches have been used to globally
proﬁle methylation levels including restriction landmark
genomic scanning [84] and microarray-based approaches [85].
Methylation has been successfully detected as a chemically
induced SNP after bisulﬁte treatment with speciﬁc oligo
arrays [86] or using a methylated DNA positive (
meC antibody)
or negative (digestion with methylation-sensitive enzymes)
DOI: 10.1371/journal.pgen.0020100.g004
Figure 4. Base Specific Cleavage for Mutation Detection
(A) Illustration of the MassCLEAVE procedure.
(A1) PCR using one primer with a T7 RNA polymerase tag and one with a universal tag.
(A2) In vitro transcription using T7 RNA polymerase and a mixture of dNTPs and NTPs.
(A3) Cleavage by RNAse A. RNAse A cleaves at pyrimidines. By adding one of the pyrimidines as dCTP or dTTP only, the positions containing CTP or TTP
are cleaved by RNAse A. Four cleavage reactions are set up in total.
Box to the right of (A): Bioanalyser trace showing a full-length 660 bp RNA produced by IVT (IVT) compared with negative control (CTRL). The final steps
involve sample conditioning and analysis by MALDI-TOF MS. Other possibilities include RNAseT1, which cleaves at a G. For methylation analysis, only
the two reverse reactions are required.
(B) Spectra and interpretation: A 396-bp fragment containing exon 6 of the EXT1 gene was analysed by MassCLEAVE to identify a heterozygous deletion
of a T at 160 bp. The informative T-forward and C-reverse reaction spectra are shown, whereby the spectrum produced by the sample under
investigation is at the top and the control underneath. The numbers at the top indicate expected peak positions along the spectrum and are indicators
of reaction quality. In the T-forward reaction, a new peak corresponding to the A1C6G3T1-composed primer appears at 3,425 Dalton (indicated by a red
arrow). In the C-reverse reaction, a new peak at 2,699 Daltons is observed, corresponding to the T1G6C1 fragment, while the height of the 3,028 Dalton
peak corresponding to the normal A1T1G6C1 fragment is reduced. The relevant normal and mutation-containing fragments are indicated and the
deleted T (or A in reverse) is underlined in red. In total, 11/15 mutations in EXT1 exon 6 and EXT2 exon 5 (associated with hereditary multiple exostosis)
were detectable with this method.
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methylation mapping [87,88]. More recently, the Golden Gate
genotyping assay on the BeadArray platform (Illumina, San
Diego, California, United States) has been successfully
adapted to detect methylation [89]. All microarray-based
approaches allow the global mapping of overall methylation
variation, but they do not offer high-resolution detection at
the level of individual CpG sites. Furthermore, these
approaches work on the assumption of extended methylation
in the region interrogated, which could limit the detection
sensitivity when complex unknown patterns of DNA
methylation are present.
MALDI-TOF MS approaches, originally developed for SNP
genotyping and SNP discovery, have been adapted to the
detection of the chemically induced SNP present in the DNA
after bisulﬁte treatment. A primer extension–based approach
in the form of the GOOD assay has been successfully
developed and used for the quantiﬁcation of methylation
levels [90]. Based on the same principle, the protocol for
allelotyping analysis as implemented in the MassARRAY
system (Sequenom) (see ‘‘Quantitative DNA analysis
applications’’) can be applied to primer extension reactions.
We have used both the MassEXTEND protocol (hME) and the
iPLEX protocol, to successfully detect and quantify
methylation at speciﬁc CpG positions (Figure 5A; S. Colella
and J. Ragoussis, unpublished data). The major disadvantage
of primer extension–based approaches, irrespective of the
detection platform, is the assay design limitation within CpG
rich regions, as it is better to avoid having a CpG site (and
therefore a potential SNP) in the sequence complementary to
the extension primer. This problem can be circumvented now
by using peptide nucleic acid probe hybridization, instead of
primer extension, to interrogate methylated CpGs. MALDI-
TOF analysis of successfully hybridized peptide nucleic acids
was shown to produce quantitative data at high sensitivity [91].
An alternative approach is based on sequencing by base
speciﬁc cleavage as described in the previous section. This
method generates different cleavage patterns for the
methylated and unmethylated CpG positions present in the
fragment analysed. This approach for methylation detection
was developed by Schatz et al. using a guanosine-speciﬁc
cleavage by RNase T1 [92]. More recently, Ehrich et al. have
developed an assay using RNase A [69], based on modiﬁcation
of the hMC SNP discovery assay. In this method only the
reverse strand is used as a template for the in vitro
transcription, followed by the two base speciﬁc
fragmentations (T-reaction examples in Figure 5B). The
spectra obtained from the two reactions are combined and
allow the quantiﬁcation of methylation at CpG sites present
in the amplicon analyzed. The ﬁnal CpG coverage achieved
depends on the amplicon size (a maximum of ;800 bp) and
the speciﬁc sequence content. The average number of CpG
DOI: 10.1371/journal.pgen.0020100.g005
Figure 5. Methylation Detection Using MALDI-TOF MS
MALDI-TOF MS spectra for the detection of different DNA methylation levels (examples shown: 100% methylated DNA; 50:50 mix of methylated and
unmethylated DNA; 10% methylated DNA samples mixed with 90% unmethylated DNA) after bisulfite treatment in specific CpG positions in the
promoter of INK4A (p16) gene (specific amplicon mapping to Chromosome 9: 21964960–21965128 on the Human Genome May 2004 assembly).
(A) Primer extension approach using iPLEX chemistry to detect DNA methylation at CpG 2 (Chromosome 9: 21965105–21965106), C call corresponding
to the methylated and T call to the nonmethylated alleles.
(B) MassCLEAVE assay using T-reverse specific cleavage, detection of the methylation levels at CpG 10–11 (Chromosome 9: 21964989–21964992 on the
Human Genome May 2004 assembly). Fragments detected on the reverse strand are as follows: 4484.85 Dalton 5OH-AAAAAAACCACAAT-3p for the
unmethylated (Unmeth) and 4516.84 Dalton 5OH-AAAAAAACCGCGAT-3p with both CpG sites methylated (Meth).
PLoS Genetics | www.plosgenetics.org July 2006 | Volume 2 | Issue 7 | e100 0926sites detected in a single amplicon is comparable to
sequencing-based approaches.
The RNA cleavage–based approach, e.g., hMC, is quite
unique and competitive in rapidly generating a
comprehensive CpG island quantitative methylation map.
The method is comparable to direct sequencing in terms of
throughput, but superior in terms of quantiﬁcation. The
quantiﬁcation in turn is comparable to a combined cloning
and sequencing approach, with the advantage that RNA
cleavage is much easier and faster to perform. The RNA
cleavage offers the possibility of detecting more CpG sites in
a single amplicon, when compared with pyrosequencing, and,
furthermore, it is independent from the extension primer
design issues. One possible limitation is that some CpG sites
cannot be analysed if they are in fragments that have a
molecular weight outside the mass detection range. Array-
based methods offer the highest throughput in detecting
multiple promoter regions in a single experiment, but at
present they do not compare to the detailed proﬁle that can
be generated with the RNA cleavage–based MALDI-TOF MS
approaches. In conclusion, the MALDI-TOF MS
resequencing–based method for methylation detection offers
a level of resolution that enables high-throughput
quantitative analysis of full CpG islands. Data generated with
this approach can lead to a better deﬁnition of complex
methylation patterns of speciﬁc regions and provide a better
understanding of the effect of speciﬁc methylation events in
the human genome.
Discussion
It is clear that MALDI-TOF MS is a versatile tool for
genomic research, allowing the analysis of DNA as well as RNA
fragments. Due to the high sensitivity and ability to quantify, it
is also suitable for clinical diagnostic use. In terms of number
of applications, it is comparable to a DNA sequencer. The
main advantages are that the technology, by measuring the
mass of DNA molecules, allows a high degree of freedom for
the individual investigator to conceive assays where the
products can be analysed by MALDI-TOF MS. Even as a
complete commercially available genomic applications
system, as offered by Sequenom or Bruker Daltonics, it is
relatively straightforward to apply custom assay design. The
other advantage is the high sample number that can be
analysed in each run, up to 3,840 samples at a time. This makes
applications such as allele-speciﬁc gene expression and high-
resolution methylation analysis very attractive for the study of
functional polymorphisms and epigenetic modiﬁcations.
Since all applications so far are based on a PCR step,
developing new tools to assess PCR primers (and where
applicable extension primers) interactions could lead to
further improvements in efﬁcient assay design and increase
the level of multiplexing, particularly in genotyping assays.
For genotyping applications, the level of multiplexing that
can be achieved with current methodology has limits. For
example, the currently used part of the spectrum is in the
4,500–9,000 Dalton range. If we leave the PCR multiplexing
issues aside, it is theoretically possible to accommodate 93
peak trios of an iPLEX reaction (extension primer and two
alleles) at 16 Dalton intervals, thus increasing the number of
reactions that can be multiplexed at current resolution levels.
This level of multiplexing would result in signiﬁcant
genotyping cost reductions.
An additional problem being addressed is that the
instruments (mass spectrometers such as Bruker Biﬂex II/III or
Autoﬂex and spotting devices) themselves are expensive and
maintenance-intensive, while high throughput applications
require the use of liquid handling systems. Both Bruker and
Sequenom offer compact, benchtop instruments in the form
of the Microﬂex (Bruker Daltonics) and the Compact
(Sequenom) to address the cost (and maintenance) issue.
One important advantage of MALDI-TOF MS that has not
been fully utilized is the sensitivity of the technology. For
example, no more than 15 nl of analyte is used on a
MassARRAY chip. This low level of reaction volume would
achieve high cost efﬁciency and could be realized with
miniaturized nanoliter scale devices (for an example see [93],
for a review see [94]). For example, the iPLEX assay takes
place in 5 llo r1 0ll volume/sample, where the costs, in broad
terms, are equally divided among PCR, extension reaction,
and chip. It is easy to calculate that such an approach will
result in signiﬁcant savings by cutting two-thirds of the cost
by a factor of ten or more. All methods described so far, such
as resequencing and expression proﬁling, are amenable to the
same cost reduction principle, and this would allow compact
MALDI-TOF MS instruments to be integrated with
miniaturized liquid handling systems.
So which applications are going to be most widely used? We
think that the genotyping assays (such as iPLEX) are going to
be the main applications. This is because current whole
genome association studies using hundreds of thousands of
SNPs will produce genomic segments or genes with disease
associations requiring further rounds of replication in
additional sample collections. Furthermore, additional SNPs
must be investigated in order to identify the ones directly
associated with disease. These downstream studies will
require genotyping technologies that offer high-cost
efﬁciency at medium levels of multiplexing and high sample
throughput, currently a role fulﬁlled by the MALDI-TOF MS–
based techniques. If further instrument development
produces compact, simple-to-use, and lower-maintenance
equipment (for example the benchtop MALDI microMX from
Waters, [Milford, Massachusetts, United States]), then the
added beneﬁts of being able to perform a wide spectrum of
additional assays will be a clear advantage. The ability to use
the same platform to perform genomic studies beyond SNP
genotyping, such as methylation detection, quantitative gene
expression, and allele-speciﬁc expression, will be a bonus
when equipment decisions have to be made for genomics and
functional genomics laboratories.
Furthermore, development of compact systems such as the
Microﬂex or MALDI microMX that can be adapted for use in
genomic or proteomic applications, will allow MALDI-TOF
MS to expand its position in the future as a versatile platform
for basic research and clinical diagnostic applications
alike. &
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